51 – 60 of 103
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
Reasons for Discontinuing Active Surveillance : Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium
(
- Contribution to journal › Article
-
Mark
Interim Results from the IMPACT Study : Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
(
- Contribution to journal › Article
-
Mark
Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re : Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961–7
(
- Contribution to journal › Letter
-
Mark
Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants
(
- Contribution to journal › Article
-
Mark
Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men
(
- Contribution to journal › Article
-
Mark
Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms
(
- Contribution to journal › Scientific review
- 2018
-
Mark
A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition : The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations
(
- Contribution to journal › Letter
-
Mark
Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men
(
- Contribution to journal › Article
-
Mark
Association Between Lead Time and Prostate Cancer Grade : Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening
(
- Contribution to journal › Article